DJDavid R. M. Jansen

David R. M. Jansen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


David R. M. Jansen has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • (on behalf of the education working group of the Dutch Society for Clinical Pharmacology

    1 shared publication
  • Biopharmacy)

    1 shared publication
  • Carolina J. P. W Keijsers

    Department of Geriatric Medicine, Jeroen Bosch Hospital, Den Bosch, The Netherlands

    1 shared publication
  • Cornelis Kramers

    Department of Pharmacology and Toxicology and Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands

    1 shared publication
  • Corrie E. Erasmus

    Department of Pediatric Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center Amalia Children's Hospital, Nijmegen, the Netherlands

    1 shared publication
  • D. S. Everaerd

    Department of Psychiatry Radboudumc Nijmegen The Netherlands

    1 shared publication

Latest Publications

  • Open Access

    Potential drug–drug interactions in males living with HIV who use drugs to treat lower urinary tract symptoms

    by David Burger, Piter Oosterhof, Karin Grintjes, Manon Marneef‐Pietersma, Frank D'ANcona, Xiaoye Zhu, Stephan Keijmel, Olivier Richel, Reinout van Crevel, David Jansen

    Objective: Lower urinary tract symptoms (LUTS) are becoming more prevalent in the ageing population of males living with HIV. Drugs to treat LUTS are known for both their potential role as victims in drug–drug interactions (DDIs) and their side effects. We aimed to evaluate the current use of drugs to treat LUTS and to assess potential DDIs in our cohort of adult males living with HIV.Design: This was a retrospective review of pharmacy records.Methods: We recorded the combination antiretroviral therapy (cART) regimen and any use of drugs to treat LUTS (anatomical therapeutic chemical codes G04CA/CB/CX and G04BD). Potential DDIs were assessed using the interaction checker developed by the University of Liverpool (https://www.hiv-druginteractions.org/checker).Results: A total of 411 adult males living with HIV were included in this analysis. The median (interquartile range [IQR]) age was 53 (41–62) years. Nineteen (4.6%) patients used one or more drugs to treat LUTS. As expected, older patients were more likely to be receiving treatment for LUTS: Q1 (20–40 years) = 0%; Q2 (41–52 years) = 2%; Q3 (53–61 years) = 7%; Q4 (62–79 years) = 10%. Seven potential DDIs between cART and LUTS treatment were noted in six of the 19 (32%) patients. Following medication reviews of these six patients, the following interventions were proposed: evaluate safe use of alpha‐blocker (n = 4), change in cART (n = 2), and dose reduction of the anticholinergic agent (n = 1).Conclusion: Treatment for LUTS coincided with cART in 7%–10% of patients aged above the median age of 53 years in our cohort. Improvements in DDI management appeared to be possible in this growing cohort of males living with HIV and with LUTS.


  • Open Access

    The etiology of rhabdomyolysis: an interaction between genetic susceptibility and external triggers

    by N. Kruijt, L. R. van Den Bersselaar, E. J. Kamsteeg, W. Verbeeck, M. M. J. Snoeck, D. S. Everaerd, W. F. Abdo, D. R. M. Jansen, C. E. Erasmus, H. Jungbluth, et al.

    Background and purpose: Rhabdomyolysis is a medical emergency characterized by acute skeletal muscle breakdown with a sudden rise and subsequent fall of serum creatine kinase (CK) levels. Rhabdomyolysis events are provoked by exposure to external triggers, possibly in combination with an increased genetic susceptibility. We aimed to describe comprehensively the external triggers and potentially pathogenic genetic variants possibly implicated in increased rhabdomyolysis susceptibility.Methods: We performed a retrospective single‐center study, including a total of 1302 patients with an acute CK level exceeding 2000 IU/l.Results: Anoxia was the most frequently reported trigger (40%). A subset of 193 patients were clinically suspected of an underlying genetic disorder (recurrent episodes, a positive family history, very high or persistently increased CK levels). In 72 of these patients, an unequivocal genetic defect was identified. A total of 22 genes with pathogenic variants were identified, including 52 different variants. Of those, 11 genes have been previously associated with rhabdomyolysis (ACADVL, ANO5, CPT2, DMD, DYSF, FKRP, HADHA, PGM1, LPIN1, PYGM, RYR1). Eleven genes are probably implicated in increased susceptibility (including AGL, CAPN3, CNBP, DMPK, MAGT1, ACADM, SCN4A, SGCA, SGCG, SMPD1, TANGO2).Conclusion: These findings suggest that the spectrum of genetic susceptibility for rhabdomyolysis has not yet been completely clarified. With the increasing availability of next‐generation sequencing in a diagnostic setting, we expect that in more cases a genetic defect will be identified.


  • Open Access

    Towards a “prescribing license” for medical students: development and quality evaluation of an assessment for safe prescribing

    by David R. M. Jansen, Carolina J. P. W Keijsers, Michiel O. Kornelissen, Marcel G. M. Olde Rikkert, Cornelis Kramers, (on behalf of the education working group of the Dutch Society for Clinical Pharmacology, Biopharmacy)

    This report describes the development and validation process of an assessment with national consensus in appropriate and safe pharmacotherapy.